Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 0858 • ACR Convergence 2025
IgA Anti-β2GPI Antibodies Drive Proatherogenic Myeloid Activation and Vascular Dysfunction in APS
Kavya Sugur¹, Chao Liu², Emily Chong³, Srilakshmi Yalavarthi⁴, Katarina Kmetova⁵, Wenying Liang⁶, Emily Becker⁶, Gavin Poppei⁶, Cyrus Sarosh⁷, NaveenKumar Somanathapura³, Ajay Tambralli³, Jason S. Knight³ and Yu (Ray) Zuo³, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ²University of Michigan, Superior Charter Twp, MI, ³University of Michigan, Ann arbor, MI, ⁴Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ⁵Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁶University of Michigan, Ann arbor, ⁷University of Michigan, Temperance, MI
Background/Purpose: Cardiovascular disease is a major cause of morbidity and mortality in antiphospholipid syndrome (APS), with rates of accelerated atherosclerosis comparable to those seen in…
Abstract Number: 0131 • ACR Convergence 2025
Libman-Sacks Endocarditis in APS: A Case-Control Study of Clinical and Serologic Features
Kyla Rodgers¹, Cyrus Sarosh², Srilakshmi Yalavarthi³, Emily Becker⁴, Yiran Shen⁵, Kaitlyn Sabb⁴, Peter Hagan⁴, Ajay Tambralli⁵, Jacqueline Madison⁵, Yu (Ray) Zuo⁵ and Jason S. Knight⁵, ¹University of Michigan, Whitmore Lake, MI, ²University of Michigan, Temperance, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ⁴University of Michigan, Ann Arbor, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Libman-Sacks endocarditis (LSE) is an inflammatory phenomenon, typically involving the mitral or aortic valve, that affects some patients with systemic lupus erythematosus (SLE) and/or…
Abstract Number: 0116 • ACR Convergence 2025
Cerebral small vessel disease in antiphospholipid syndrome: subtypes and total burden of cSVD on MRI
Chun Li¹, Jianping Guo², Yangyi Fan¹, Yu Kang¹ and Xiaodan Hu¹, ¹Peking University People's Hospital, Beijing, China (People's Republic), ²Peking University People's Hospital, Beijing, Beijing, China
Background/Purpose: Cerebrovascular diseases are common and severe neurological complications in antiphospholipid syndrome (APS). However, few studies focused on cerebral small vessel disease (cSVD) in APS.…
Abstract Number: 0857 • ACR Convergence 2025
CD14-dependent MAP kinase signaling is required for pathogenic neutrophil extracellular trap formation in APS
Thalia Newman¹, NaveenKumar Somanathapura¹, Chao Liu², Srilakshmi Yalavarthi¹, Pooja Kapoor¹, Ajay Tambralli¹, Jacqueline Madison¹, Yu (Ray) Zuo¹ and Jason S. Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Superior Charter Twp, MI
Background/Purpose: Antibodies targeting beta-2-glycoprotein I (anti-β2GPI) promote inflammation and thrombosis in antiphospholipid syndrome (APS). It has been shown that anti-β2GPI activate neutrophils through Toll-like receptor…
Abstract Number: 0132 • ACR Convergence 2025
Increased Expression of Gas6 and Its Tyrosine Kinase Receptor Tyro3 Are Associated with Antiphospholipid Syndrome
Fanshu Li, Ranran Yao, Fanlei Hu, Liling Xu and Chun Li, Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic)
Background/Purpose: Growth arrest specific protein 6 (Gas6) is a member of the vitamin K-dependent protein family. It participates in apoptosis, inflammatory response and immunomodulation by…
Abstract Number: 0115 • ACR Convergence 2025
Dysfunctional Mitophagy Propels Neutrophil Hyperactivity and Thrombosis in Antiphospholipid Syndrome
Ajay Tambralli¹, Emily Becker², Kaitlyn Sabb³, NaveenKumar Somanathapura¹, Srilakshmi Yalavarthi¹, Cyrus Sarosh⁴, Jacqueline Madison¹, Yu (Ray) Zuo¹ and Jason S. Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan - Ann Arbor, Ann Arbor, MI, ⁴University of Michigan, Temperance, MI
Background/Purpose: Neutrophil hyperactivity and neutrophil extracellular trap (NET) release (NETosis) contribute to antiphospholipid syndrome (APS) pathogenesis. We recently discovered that APS patient neutrophils have more…
Abstract Number: 2599 • ACR Convergence 2025
Identification of a New Pathogenic Axis in Antiphospholipid Syndrome Linking Antiphospholipid Antibodies, Liver Function, and Circulating Proatherogenic Metabolites
Beatriz Vellón-García¹, Sagrario Corrales-Díaz-Flores², MARIA ANGELES AGUIRRE ZAMORANO³, Ismael Sanchez-Pareja³, Laura muñoz-Barrera³, Tomás Cerdó³, Pedro Seguí-Azpilcueta⁴, Christian Merlo², Maria del carmen abalos-aguilera², Nuria Barbarroja⁵, Rafaela Ortega-Castro⁶, José-Antonio Gonzalez-Reyes⁷, Alejandro Escudero-contreras², Chary López pedrera⁸, Jose manuel Villalba⁹ and Carlos Pérez Sánchez¹⁰, ¹Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, ²Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁴Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ⁵Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁷Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA³)., Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁹Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: This study aims to:1- Characterize the circulating metabolomic signature in APS patients; 2- Investigate the role of hepatic involvement in the pathophysiology of APS;…
Abstract Number: 0856 • ACR Convergence 2025
Integrated Single-Cell and Spatial Transcriptomics Reveal Vascular and Immune Pathogenesis in APS Nephropathy
Shuyi Yu¹, Haoyu Pan¹, Jinyi Qian¹, Xiaohan Wei², Yuying Fan¹, Zhixia Yang¹, Shiyan Gu¹, Jianzhou Wu¹, Cenyi Wang¹, Tiancheng Zhou¹ and Hui Shi³, ¹Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ²Shanghai JiaoTong University, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To elucidate the molecular and cellular mechanisms underlying antiphospholipid antibody (aPL) nephropathy using integrated single-cell and spatial transcriptomic (SP) profiling of kidney tissues.Methods: Renal…
Abstract Number: 0130 • ACR Convergence 2025
Plasminogen activator inhibitor 1 increases thrombotic risk in Antiphospholipid syndrome
Koshy Nithin Thomas¹, Pratibha Singh², Anu Balakrishnan³, Amita Aggarwal⁴ and Able Lawrence⁵, ¹Christian Medical College, Vellore, Tamil Nadu, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Post Graduate Institute, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁵SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India
Background/Purpose: Antiphospholipid antibody syndrome (APS) is a common cause for acquired thrombophilia. The group termed ‘seronegative’ APS has not made any headway in the revised…
Abstract Number: 2403 • ACR Convergence 2025
Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis
Jaime Flores-Gouyonnet¹, Erika Navarro-Mendoza¹, Mario Bautista-Vargas¹, Ali Ardekani¹, Maria Cuellar-Gutierrez¹, Gabriel Figueroa-Parra², Mariana Gonzalez-Treviño³, Alain Sanchez-Rodriguez⁴, Andrew C. Hanson¹, Cassondra Hulshizer⁵, Cynthia Crowson⁶ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Vanderbilt University Medical Center, Nashville, TN, ⁴ABC Medical Center, Ciudad de México, Federal District, Mexico, ⁵Mayo Clinic, Rochester, ⁶Mayo Clinic, Stewartvillle, MN
Background/Purpose: SLE is clinically heterogeneous and associated with increased hospitalizations. However, it remains unclear which patient subgroups drive this excess in unplanned healthcare use. We…
Abstract Number: 0855 • ACR Convergence 2025
Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial
Jane Salmon¹, Mimi Kim², Marta Guerra¹, Joseph Worden³, Carl Laskin⁴, Maria DeSancho⁵, Inna Landres⁵, Jason S. Knight⁶, Haley Slosberg¹, Margaret Minett¹ and Ware Branch⁷, ¹Hospital for Special Surgery, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³University of Utah School of Medicine, Salt Lake City, ⁴University of Toronto, Toronto, ON, Canada, ⁵Weill Cornell Medicine, New York, ⁶University of Michigan, Ann Arbor, MI, ⁷University of Utah Health Sciences Center, Salt Lake City, UT
Background/Purpose: The IMPACT trial (NCT03152058) showed that certolizumab appears effective in preventing placenta-mediated adverse pregnancy outcome (APO) in high-risk antiphospholipid syndrome (APS) patients. We have…
Abstract Number: 0128 • ACR Convergence 2025
Defining a Consensus for Critical Data Fields for International Pediatric Antiphospholipid Syndrome Research
Jheel Bhatt¹, Elizabeth Sloan², Selcan Demir³, Mojca Avramovic⁴, Seza Özen⁵, Doruk Erkan⁶ and Tadej Avcin⁷, ¹Advent Health Orlando, Orlando, FL, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³Eskisehir Osmangazi University, Eskişehir, Turkey, ⁴University Children's Hospital, Ljubljana, Slovenia, ⁵Hacettepe University Medical Faculty, Ankara, Turkey, ⁶Hospital for Special Surgery, New York, NY, ⁷University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a rare, thrombo-inflammatory autoimmune disease characterized by thrombosis and nonthrombotic manifestations in patients with persistent positive antiphospholipid antibodies, with…
Abstract Number: 2209 • ACR Convergence 2025
Pregnancy outcomes in Systemic Lupus Erythematosus: Insights from a multicenter Spanish Study on the impact of antiphospholipid antibodies and APS
cristiana Sieiro¹, Jose Ordas Martínez², Ana Merino³, Helena Amar Muñoz⁴, Stefanie Burger⁵, Ignacio Braña Abascal⁵, Carmen Jose Mendéz⁶, Raquel Dos Santos Sobrín⁷, Jose Luis Puga Guzman⁷, Ricardo Blanco⁸ and Víctor Taboada Martínez³, ¹Univrsity of Manchester, Manchester, United Kingdom, ²Complejo Asistencial Universitario de León, León, Spain, ³Hospital Universitario Marqués de Valdecilla, Santader, Spain,, Santander, Spain, ⁴Hospital General Universitario Gregorio Marañón, Rheumatology, Madrid, Spain, Madrid, Spain, ⁵Hospital Universitario Central de Asturias, Rheumatology, Oviedo, Spain, Oviedo, Spain, ⁶Complexo Hospitalario Universitario A Coruña, Rheumatology, A Coruña, Spain, Coruña, Spain, ⁷Hospital Universitario de Santiago de Compostela, Rheumatology, Santiago de Compostela,, Santiago de Compostela, Spain, ⁸Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Pregnancy in patients with systemic lupus erythematosus (SLE) is associated with significant maternal and obstetric risks, particularly in the context of antiphospholipid syndrome (APS).…
Abstract Number: 0144 • ACR Convergence 2025
Duration of Anticoagulation in Antiphospholipid Antibody-positive Patients: Results from an AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Survey
Zeynep Belce Erton¹, Joann Vega², Hannah Cohen³ and Doruk Erkan², ¹Hospital for Special Surgery, Brooklyn, NY, ²hospital for special surgery, New York, NY, ³University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: APS ACTION is a multidisciplinary, international research network focused on developing collaborative studies to improve antiphospholipid syndrome (APS) diagnosis and management. There is limited…
Abstract Number: 0129 • ACR Convergence 2025
Analysis of Antiphosphatidylserine/prothrombin Antibodies as a Predictor of Lupus Anticoagulant in the Pediatric Population
Jonathan Marilao¹, Sean Yates² and Elizabeth Sloan³, ¹University of Texas Southwestern, Dallas, TX, ²University of Texas Southwestern, Dallas, ³UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX
Background/Purpose: Antiphospholipid Syndrome (APS) is a systemic thromboinflammatory autoimmune disease characterized by thrombotic or obstetric events occurring in individuals with persistently positive antiphospholipid antibodies (aPL).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].